Syte.Biotech
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Syte.Biotech firmographics
Firmographics- Name
- Syte.Biotech
- Legal name
- SYTE.bio
- Website
- https://syte.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Syte.Biotech industry classification
Industry- Product category
- Biopharmaceutical Gene Therapy and Nucleic Acid Vaccines
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)
Keywords
Where Syte.Biotech is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Syte.Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical/Biotech Product Revenue: Pre-commercial clinical-stage company developing DNA and RNA-based vaccines and gene therapies for humans and animals. Revenue model would likely come from product sales upon regulatory approval.
Syte.Biotech product offering
Product offeringCore offering
Syte.Biotech is a clinical-stage synthetic biology company that develops non-viral DNA and RNA-based vaccines and gene therapies for humans and animals. It commercializes five proprietary nucleic-acid platform technologies (SYTE Linear DNA, SYTE Circular DNA, SMART-DNA, SYTE-cRNA, and SYTE Linear RNA) that enable patients' tissues to autonomously generate therapeutic agents, and applies these platforms across Human Health and Animal Health pipelines covering infectious disease vaccines, chronic disease therapies, and oncology.
Product overview
SYTE.bio is a clinical-stage synthetic biology company offering a unified portfolio of non-viral DNA and RNA therapeutic platforms designed for safety, stability, and efficacy. The core technology stack consists of three DNA platforms (SYTE Linear DNA Platform, SYTE Circular DNA Platform, and SMART-DNA) and two RNA platforms (SYTE-cRNA Platform and SYTE Linear RNA Platform). These platforms enable patients' tissues to autonomously generate therapeutic agents by directly modifying molecular blueprints. The company applies these platforms across two therapeutic areas—Human Health and Animal Health—with specialized pipelines covering infectious diseases, chronic non-communicable diseases, and oncology. The DNA and RNA platforms support diverse therapeutic applications from prophylactic vaccines to gene therapies, with expression timelines tailored to disease demands ranging from short-term interventions to long-term solutions.
Differentiator
Problem solved
Functional benefit
Products and services
- SYTE Linear DNA Platform (L-DNA) A next-generation linear DNA vector engineered for high efficiency, safety, and scalability, featuring covalently closed ends with hairpin loop structures, DNA Nuclear Transporting Sequences (DNTS) for improved nuclear entry, torsion-free design, and non-viral non-integrative properties enabling re-dosable therapy for vaccine and gene-therapy developers.
- SYTE Circular DNA Platform (C-DNA) A minicircle DNA platform free of antibiotic resistance markers, optimized for vaccines and short- and long-term therapies, featuring circular supercoiled double-stranded DNA with exonuclease resistance and multiple gene expression versions for vaccine and gene-therapy developers.
- SMART-DNA Platform A structured, modular, adaptive, responsive and targeted DNA platform engineered for self-delivery without lipid nanoparticles or electroporation, offering non-viral, non-integrative design with high enzymatic stability, freeze-dry storage capability, and re-dosability for vaccine and gene-therapy developers.
- SYTE-cRNA Platform (Circular RNA) A novel circular RNA platform engineered for stability and enhanced protein expression, featuring a covalently closed structure free from 5'-cap and 3'-poly(A) tail that confers exonuclease resistance, sustained protein production, reduced immunogenicity, and re-dosability for vaccine and therapeutic developers.
- SYTE Linear RNA Platform A novel linear RNA platform engineered for stability and enhanced protein expression, featuring structured ends free from 5'-cap and 3'-poly(A) tail that enable sustained protein production via translation initiation sequences and efficient encapsulation into delivery systems such as lipid nanoparticles.
- Human Health Vaccine Pipeline
Companies that use Syte.Biotech
Customer profileSegments2 records
Ideal customer profiles2 records
Syte.Biotech technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Syte.Biotech partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights5 records
Syte.Biotech competitors and assessment
Company assessmentEmerging players
- Tiba Biotech: Early-stage developer of RNA delivery technologies, including non-LNP approaches. Comparable to SYTE.bio's SMART-DNA self-delivery concept and nucleic acid vaccine work.
- Verve Therapeutics: Clinical-stage company developing in vivo DNA/RNA gene editing medicines for cardiovascular disease. Comparable in applying non-viral nucleic acid delivery for human therapeutics.
- eTheRNA immunotherapies: Clinical-stage mRNA immunotherapy company focused on cancer and infectious disease vaccines. Comparable to SYTE.bio's vaccine and oncology pipelines built on RNA platforms.
Direct peers
- Moderna: Commercial leader in mRNA therapeutics and vaccines. SYTE.bio competes in the same non-viral RNA therapeutic space, including circular/linear RNA approaches for vaccines and protein expression.
- Arcturus Therapeutics: Developer of RNA medicines including self-amplifying RNA and circular RNA. Closely comparable to SYTE.bio's circular RNA (SYTE-cRNA) and linear RNA platform approaches.
- BioNTech: mRNA therapeutics company developing vaccines and cancer immunotherapies. Direct overlap with SYTE.bio's human vaccine and oncology pipelines built on nucleic acid platforms.
- CureVac: Clinical-stage mRNA therapeutics company with proprietary RNA platform technology. Comparable to SYTE.bio's RNA platforms and vaccine pipeline.
- Generation Bio: Clinical-stage company developing non-viral DNA-based gene therapies using closed-ended DNA. Closely comparable to SYTE.bio's SYTE Linear DNA (L-DNA) and SYTE Circular DNA (C-DNA) platforms.
Broad incumbents
- Elanco Animal Health: Major animal health company with vaccine, therapeutics, and oncology portfolios. Comparable commercial target for SYTE.bio's animal health pipeline partnerships and licensing opportunities.
- Zoetis: Largest pure-play animal health company with established vaccine and therapeutics franchises. Overlaps with SYTE.bio's animal health pipeline including veterinary oncology and infectious disease vaccines.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Syte.Biotech social profiles
Digital presenceSyte.Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Syte.Biotech leadership team
Management profileNumber of profiles
Profiles7 records
Syte.Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Syte.Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Syte.Biotech
What does Syte.Biotech do?
Syte.Biotech is a clinical-stage synthetic biology company that develops non-viral DNA and RNA-based vaccines and gene therapies for humans and animals. It commercializes five proprietary nucleic-acid platform technologies (SYTE Linear DNA, SYTE Circular DNA, SMART-DNA, SYTE-cRNA, and SYTE Linear RNA) that enable patients' tissues to autonomously generate therapeutic agents, and applies these platforms across Human Health and Animal Health pipelines covering infectious disease vaccines, chronic disease therapies, and oncology.
Is Syte.Biotech a public or private company?
Syte.Biotech is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Syte.Biotech founded?
Syte.Biotech was founded in 2021. It employs 1 to 10 people.
Where is Syte.Biotech based?
Syte.Biotech is headquartered in Boston, United States, in the North America region.
How does Syte.Biotech make money?
One revenue line is on record: pharmaceutical/Biotech Product Revenue.
Who are Syte.Biotech's main competitors?
Emerging players on record are Tiba Biotech, Verve Therapeutics and eTheRNA immunotherapies. Direct peers are Moderna, Arcturus Therapeutics, BioNTech, CureVac and Generation Bio. Broad incumbents are Elanco Animal Health and Zoetis.
Does Syte.Biotech have an API?
No public API is recorded for Syte.Biotech.
What industry is Syte.Biotech in?
Syte.Biotech's product category is Biopharmaceutical Gene Therapy and Nucleic Acid Vaccines. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.